Close

Axsome Therapeutics (AXSM) Announces Collaboration with Duke University Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation

December 14, 2017 7:26 AM EST Send to a Friend
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login